Abstract:Abstract Background As a leading cause of nosocomial infections, Klebsiella pneumoniae poses a significant threat due to its propensity to acquire resistance to many classes of antibiotics, including carbapenems. Gastrointestinal (GI) colonization by K. pneumoniae is a risk factor for subsequent infection as well as transmission to other patients. To study this crucial step in pathogenesis, we developed a mouse model of K. pneumoniae GI colonization using a clinically relevant parenteral antibiotic regimen. Methods To improve the clinical relevance of our model, we elected to use intraperitoneal injections of vancomycin, one of the most highly utilized antibiotics in the United States. Results To optimize dosage in C57bl/6 mice, we injected 20mg/kg, 350mg/kg, or vehicle (PBS) for three days prior to gastric gavage with 108 colony forming units (CFU) of a low-resistance strain of K. pneumoniae. The mice who received 350mg/kg (a mouse equivalent of a human dose of 1g/day calculated through the FDA guidelines for estimating safe dosing) shed about 107 CFU/g of feces at Day 7 while those receiving the lower dose or vehicle shed 104 CFU/g. Next, we compared 3- or 5-day pre-treatments with vancomycin prior to inoculation with an ST258 (epidemic carbapenem-resistant) strain. At Day 7 post-inoculation, mice who received 5 days shed 1010 CFU/g feces while those who received vancomycin for 3 days or vehicle for 5 days (PBS) shed 106 or 104 CFU/g feces respectively. Thus, we chose 5 days of 350mg/kg vancomycin injection as our regimen for inducing robust GI colonization in mice. Finally, we tested the durability of colonization by following fecal shedding in mice up to Day 60 post-inoculation with a second ST258 strain. Shedding during the first 7 days occurs at about 1010 CFU/g feces, and from day 14 to day 60 fecal loads are stable around 107 CFU/g feces. Results are comparable between male and female mice. Conclusion In conclusion, we have developed a mouse model of robust, prolonged GI colonization with multiple strains of K. pneumoniae using controlled dosing of a clinically relevant antibiotic. This model may be used to study a key step in K. pneumoniae pathogenesis and infection prevention in the future. Disclosures All Authors: No reported disclosures

Animal models of Klebsiella pneumoniae mucosal infections

Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance

The Response of Murine Gut Microbiome in the Presence of Altered rpoS Gene of Klebsiella pneumoniae

Differential mucosal tropism and dissemination of classical and hypervirulent Klebsiella pneumoniae infection

Klebsiella pneumoniae vaccine studies in animal models

Pathophysiological effects of Klebsiella pneumoniae infection on Galleria mellonella as an invertebrate model organism

Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development

Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia

The germfree murine animal: an important animal model for research on the relationship between gut microbiota and the host.

Murine Acute Pneumonia Model of Pseudomonas Aeruginosa Lung Infection

Klebsiella pneumoniae Biofilms and Their Role in Disease Pathogenesis

Modelling Legionnaires' disease: Lessons learned from invertebrate and vertebrate animal models

The use of organ cultures and animal models in the study of Mycoplasma pneumoniae infections

Klebsiella in Wildlife: Clonal Dynamics and Antibiotic Resistance Profiles, a Systematic Review

995. A Murine Model of Klebsiella pneumoniae Gastrointestinal Colonization with Parenteral Vancomycin Administration

Different Metabolic Profiles of K1 Serotype and Non-Serotype K1 and K2 Klebsiella Pneumoniae Isolates in Oral Infection Mice Model

Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Animal infection models using non‐mammals

Virulence Factors in Klebsiella pneumoniae: A Literature Review

Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases.